Tarlatamab在既往治疗的小细胞肺癌中的持续临床获益及颅内活性：DeLLphi-300试验最新进展

文章预览

SCI 14 September 2024 Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer:DeLLphi-300 Trial Update （Journal of Clinical Oncology；IF：42.1） Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553. Epub ahead of print. PMID: 39208379. CORRESPONDING AUTHOR :Afshin Dowlati, MD, University Hospitals Seidman Cancer Center and Case Western,Reserve University, Cleveland, OH.e-mail: afshin.dowlati@case.edu. ABSTRACT 摘要 Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has shown durable anticancer activity and manageable safety in previously treat ………………………………